PDGFRA and hypereosinophilic syndrome: For example, imatinib is considered a definitive treatment for patients with HES in myeloid neoplasms (usually MDS/MPNs) and FIP1L1-PDGFRA rearrangement or PDGFRA/B-re-arranged neoplasms [29].